gabatar CAR T-cell far a Singapore – wata hanya mai ban sha'awa da juyin juya hali don maganin ciwon daji. Cibiyar Ciwon daji ta Jami'ar Kasa, Singapore (NCIS) ta kirkiro wani sabon tsarin maganin da ke amfani da tsarin rigakafi don yaki da ciwon daji. Ba kamar na al'ada chemotherapy ba, CAR T Cell Therapy an keɓance shi, ta amfani da gyare-gyaren ƙwayoyin jinin majiyyaci don keɓancewa da kawar da ƙwayoyin kansa. Amfani da ƙwayoyin gamma-delta T daga masu ba da gudummawa lafiya suna haɓaka ingancin ƙwayoyin CAR-T yayin da yuwuwar rage farashin jiyya, yana sa wannan jiyya ya fi kyau. Wannan hanyar, wanda CytoMed Therapeutics ya haɓaka, tana wakiltar babban ci gaba a yankin. Hukumar Kiwon Lafiyar Kiwon Lafiya ta amince da wani gwaji na asibiti kashi na 1 wanda zai dauki masu ba da gudummawar jini lafiya don gwaji da marasa lafiya da ke fama da cututtukan daji masu juriya don magani. Wannan dabarar da ba ta keɓanta ba tukuna mai inganci tana da yuwuwar inganta kula da cutar kansa a Singapore, tana ba da bege da sabbin dama ga marasa lafiya da danginsu.
CAR T-Cell Far A Singapore - Matsayin Yanzu
CAR-T tantanin halitta ya zama mai canza wasa a yadda ake maganin ciwon daji, kuma Singapore ta yi farin ciki sosai game da wannan sabon magani. Kasar Singapore ta sami ci gaba da yawa a cikin ɗaukar magungunan CAR-T ta hanyar gwaji na asibiti, haɗin gwiwa, da goyon bayan tsari. Wannan ya taimaka wa marasa lafiya kuma ya ba da gudummawa ga inganta kulawar ciwon daji. Kasar Singapore har yanzu tana kan gaba a fannin maganin tantanin halitta na CAR-T saboda tana ci gaba da yin bincike kuma tana da tsarin kiwon lafiya mai kyau. CAR T-Cell far a Singapore ya sami saurin gudu, yana baiwa masu fama da cutar kansa da iyalansu bege.
Tare da adadin gwaje-gwaje na asibiti da ke faruwa a Asibitin Jami'ar Kasa, Singapore, Chimeric Agent Receptor (CAR) T-cell far yana tasowa cikin sauri sosai a Singapore. Oscar Saxelby-Lee yana fama da cutar sankarar bargo ta lymphoblastic, cutar da ta bijire wa duk wani magani. Yarinyar mai shekaru biyar daga Burtaniya ta je Singapore ne don wani aikin da ba a taba yi wa wani jariri daya a doron kasa ba. Yaron ya tashi ne daga Worcester, Ingila, don wani sabon nau'in magani wanda ya ƙunshi zana ƙwayoyin rigakafi daga jinin majiyyaci tare da dasa su da Chimeric Antigen Receptor (CAR-T).
Hukumar Kimiyyar Kiwon Lafiya ta Singapore (HSA) ya amince da Kymriah (tisagenlecleucel) a matsayin farkon kasuwanci na chimeric antigen receptor T-cell (CAR-T) a cikin Singapore a ƙarƙashin sabon salon salula, nama, da samfuran jiyya (CTGTP). HSA ta amince da Kymriah don kula da yara da matasa marasa lafiya daga shekaru 2 zuwa 25 tare da cutar sankarar jini mai tsanani na B-cell (ALL) wanda ke da wuyar gaske, a sake dawowa bayan dasawa ko a karo na biyu ko daga baya; da kuma kula da tsofaffi marasa lafiya tare da relapsed ko refractory (r / r) yada babban B-cell lymphoma (DLBCL) bayan biyu ko fiye Lines na tsarin far.
Mai karɓa yana ɗaure da wani sunadari a cikin ƙwayoyin kansa, yana haifar da ƙwayoyin CAR-T don kunnawa da lalata ƙwayoyin cutar kansa. Tunda kwayoyin cutar sankarar bargo sun kwaikwayi tsarin garkuwar jiki na Oscar, wannan nau'i na maganin CAR-T na musamman ne kuma ya fi rikitarwa, a cewar Mataimakin Farfesa Allen Yeoh, shugaban ilimin cututtukan cututtukan yara a Asibitin Jami'ar Kasa (NUH). Oscar zai kasance mutum na biyu a duniya da zai yi wannan aikin. An yi wa yaron farko magani Nuhu shekaru kadan baya.
CAR-T cell far wani sabon nau'in magani ne wanda ya canza yadda mutane a duk faɗin duniya suke magance cutar kansa. Singapore, wacce aka santa da tsarin kiwon lafiyarta na fasaha da kayan aikin bincike, tana ɗaya daga cikin wurare na farko don karɓa da amfani da jiyya na CAR-T. A cikin wannan yanki, za mu yi magana game da inda magungunan CAR-T yake a yanzu a Singapore da kuma yadda yake shafar masu cutar kansa.
Singapore tana da wuraren kiwon lafiya da cibiyoyin karatu waɗanda ke cikin mafi kyawun duniya. Waɗannan wurare sun kasance masu mahimmanci ga ci gaban maganin ƙwayoyin cuta na CAR-T. Cibiyoyi kamar Cibiyar Ciwon daji ta Singapore (NCCS), Cibiyar Ciwon daji ta Jami'ar Singapore (NCIS), da Babban Asibitin Singapore (SGH) sun shiga cikin gwaje-gwaje na asibiti, nazarin bincike, da kuma ba da magungunan CAR-T ga marasa lafiya.
Ta hanyar nazarin asibiti daban-daban, CAR-T tantanin halitta ya sami ci gaba mai yawa a Singapore. Nau'o'in ciwon daji daban-daban, kamar cutar sankarar bargo, lymphoma, da ciwace-ciwacen ciwace-ciwace, sune aka fi mayar da hankali kan waɗannan karatun. Sakamakon ya kasance mai ƙarfafawa, yana nuna yawan amsawa da kuma tsawon lokacin gafara. Kyakkyawan sakamako ya ba da damar masu gudanarwa su amince da maganin tantanin halitta CAR-T, wanda ke nufin yanzu ana iya amfani dashi a cikin aikin asibiti.
Za a yi amfani da maganin tantanin halitta na CAR-T ne kawai idan yana da sauƙin samu kuma baya tsada sosai. Kasar Singapore ta dauki matakai don tabbatar da cewa mutane za su iya samun wannan sabon magani. Tare da cibiyoyin kiwon lafiya, Ma'aikatar Lafiya ta yi aiki a kan ƙirƙirar jagorori da tsarin biyan kuɗi don sauƙaƙa wa marasa lafiya samun maganin ƙwayar cuta ta CAR-T.
Tsarin yanayin kiwon lafiya na Singapore yana ba da fifiko sosai kan haɗin gwiwa tsakanin ma'aikatan kiwon lafiya, masana ilimi, da kasuwanci. Singapore ta sami damar shiga cikin nazarin ilimin halittar jiki na CAR-T na duniya godiya ga haɗin gwiwa tare da manyan kamfanonin biopharmaceutical na duniya. Irin waɗannan yarjejeniyoyin sun haɓaka bincike, sun sa jiyya sun fi tasiri, kuma sun ba mutane da yawa damar samun hanyoyin kwantar da hankali.
Maganin ƙwayoyin CAR-T a Singapore yana kama da zai sami makoma mai haske. Binciken da ake ci gaba da yi yana mai da hankali ne kan samar da maganin tantanin halitta na CAR-T mafi inganci da aminci, rage illolin jiyya, da kuma gano hanyoyin amfani da shi don yawan cututtukan daji. Singapore wata cibiya ce ta kirkire-kirkire ta hanyar CAR-T saboda tana da himma ga bincike da haɓakawa kuma tana da kyakkyawan yanayi na doka.
Menene Kwayoyin CAR-T Kuma Ta Yaya Suke Rusa Kwayoyin Cutar Cancer?
CAR T cells, also known as Chimeric Antigen Receptor T cells, are immune cells that play an important part in CAR T Cell Therapy. These specialized T cells are engineered in a laboratory to express a chimeric antigen receptor on their surface. CAR T cells, also known as Chimeric Antigen Receptor T cells, are immune cells that play an important part in CAR T Cell Therapy. In a laboratory, these specialized T cells are designed to express a chimeric antigen receptor on their surface. This receptor is programmed to recognize specific proteins on the surface of cancer cells known as antigens. When the CAR T cells are identified by the immune system, they bind to the cancer cells, triggering a robust immune response. Kwayoyin CAR T that have been activated grow and launch a targeted attack on cancer cells, effectively destroying them.
Wadanne Sharuɗɗa Za'a Iya Magance Ta CAR T Therapy A Singapore?
CAR T Cell Therapy wani nau'i ne na ci-gaba na rigakafi wanda ya nuna tasiri mai mahimmanci wajen magance takamaiman yanayi, musamman niyya ga marasa lafiya da ke fuskantar kalubalen yanayi. Wannan ci-gaban jiyya ya dace sosai ga mutanen da aka gano tare da sake dawo da mugayen nau'ikan cutar sankarar bargo na Lymphoblastic (ALL), myeloma da yawa, da kuma lokuta na sake dawowa a cikin Non-Hodgkin Lymphoma, kamar Diffuse Large B-cell Lymphoma (DLBCL). Wannan yana da mahimmanci musamman lokacin da magungunan gargajiya suka gaza kuma aƙalla hanyoyin jiyya guda biyu da suka gabata sun tabbatar da rashin tasiri wajen cimma sakamakon da ake so. Don haka, CAR T-Cell Therapy ya fito a matsayin zaɓin magani mai ban sha'awa ga marasa lafiya da ke fama da cutar sankarar bargo da lymphoma, yana ba su haske na bege da alƙawarin ingantaccen sakamakon jiyya a Singapore.
Mafi Sauƙin Tsarin Samun CAR T Cell Therapy
Aika rahotonku
Aika imel zuwa info@cancerfax.com tare da tarihin likitan ku da bayananku, gami da gwaje-gwajen jini da dubawa. Wannan yana taimaka mana mu tantance halin da ake ciki da kuma jagorance ku zuwa mafi dacewa maganin cutar kansa.
Kima & Ra'ayi
Za mu taimake ku samun takardar izinin likita da shirya shirye-shiryen balaguron ku don tabbatar da tafiya mai sauƙi don murmurewa daga wannan cuta.
Visa na likita da tafiya
Ƙwararrun ma'aikatanmu za su yi la'akari da rahotannin ku sosai kuma su ba da cikakken jarrabawa da shawarwarin ƙwararrun da ke ba da shawarar asibitoci da kwararru masu dacewa.
Jiyya & Bibiya
Tawagar mu masu sadaukarwa za su ci gaba da raka ku a duk lokacin aikin jiyya da zarar kun isa asibitin da kuka fi so.
Me yasa zabar Singapore don maganin CAR T-Cell?
Advanced Medical Infrastructure
An san Singapore don fasahar zamani da wuraren kiwon lafiya na duniya. Gwamnati ta sanya kudi da yawa a fannin kiwon lafiya kuma tana da tsarin da yake da karfi kuma ya kai matsayin kasa da kasa. A cikin 2010, WHO ta sanya tsarin kula da lafiyar Singapore a matsayi na shida cikin 100 mafi kyau a duniya. A halin yanzu, asibitoci 22 da sauran wuraren kiwon lafiya a Singapore sun sami amincewar Hukumar Hadin Kan Duniya (JCI).
Kwararrun Kwararrun Likitanci
Kasar Singapore tana da ƙwararrun ƙwararrun ƙwararrun likitoci da ƙwararrun likitoci, waɗanda suka haɗa da ƙwararrun ƙwararrun ƙwayoyin cuta da masu ilimin halittar jini waɗanda suka ƙware a maganin ƙwayar cuta ta CAR-T. An horar da waɗannan ƙwararrun a Amurka da ƙasashen waje, kuma yawancinsu sun yi aiki ko karatu a sanannun cibiyoyin kiwon lafiya a ƙasashen waje.
Matsakaicin Dokoki Da Kula da Inganci
Kasuwancin kiwon lafiya a cikin Singapore ana sarrafa shi ta tsauraran ƙa'idodi da ingantaccen bincike. Jami'an kiwon lafiya a cikin ƙasa, kamar Hukumar Kimiyyar Kiwon Lafiya (HSA), tabbatar da cewa jiyya, kamar CAR-T cell far, sun cika ƙaƙƙarfan ƙa'idodi don aminci da inganci. Wannan yana ba marasa lafiya na ƙasashen waje waɗanda ke son samun magani a Singapore kwanciyar hankali.
Muhallin Al'adu da yawa da Ingilishi
Singapore birni ne da ke da al'adu da jama'a daban-daban, kuma Ingilishi ɗaya ne daga cikin harsunan da aka sani. Wannan ya sa ya zama wuri mai kyau ga marasa lafiya na kasashen waje don zuwa saboda sadarwa yana da sauƙi da sauri. Marasa lafiya daga wasu ƙasashe suna iya magana da likitocinsu cikin sauƙi, koyan hanyoyin magani, kuma a kula da damuwarsu ta likitanci.
Tsarin Magani na CAR-T Cell Therapy
Tsarin Jiyya na Kwayoyin CAR-T ya ƙunshi manyan matakai masu zuwa:
Shawarar farko:
Majinyacin da ke fama da ciwon daji dole ne ya tuntubi wani likitan dabbobi don tattauna cancantarsa ta CAR-T Cell Therapy.
Likitan zai yi cikakken tarihin likita da kuma tantance majiyyaci.
Bayan kimantawa, za a sanar da majiyyaci game da kasada, fa'idodi, da tsammanin maganin.
Tarin Kwayoyin Halitta da Gyara:
Ana tattara ƙwayoyin T daga majiyyaci ta hanyar dabara mai kama da gudummawar jini da ake kira apheresis.
Waɗannan ƙwayoyin T an ƙera su ta hanyar ilimin halitta a cikin dakin gwaje-gwaje don bayyana mai karɓar antigen na chimeric (CAR).
Kwayoyin da aka gyaggyarawa ana haɓaka su kuma ana haɓaka su don samar da isasshen adadin ƙwayoyin CAR T.
Hanyar jiko:
Don samar da yanayin da ya dace da ayyukan tantanin halitta na CAR T, majiyyaci yana tafiya ta hanyar daidaitawa, wanda yawanci ya haɗa da ƙananan ƙwayoyin cuta.
Kwayoyin CAR T da aka gyaggyarawa ana saka su a cikin jinin majiyyaci.
Kwayoyin CAR T suna yawo a cikin jiki, ganowa da haɗawa ga ƙwayoyin kansa da ke bayyana takamaiman antigens.
Kulawa da Bibiya:
Bayan duk tsarin jiko, za a sa ido sosai ga mai haƙuri don tasirin sakamako masu illa da kuma maganin warkewa.
Ana tsara alƙawuran biyo baya akai-akai don duba ingancin jiyya da magance duk wata damuwa mai tasowa.
Saka idanu na dogon lokaci yana tabbatar da sakamako masu amfani kuma yana magance duk wani matsala mai mahimmanci a cikin marasa lafiya na ciwon daji.
Menene Kudin CAR T Cell Therapy A Singapore?
Kymriah CAR T-cell far, wanda Singapore Medical Council ta amince da maganin yaduwa manyan B-cell lymphoma da B-cell m lymphoblastic cutar sankarar bargo, na iya kudin har zuwa $475,000 USD watau a kusa da $ 700,000 SGD.
CAR T-Cell Kwararrun Farfadowa A Singapore
Ɗauki ra'ayi na biyu na ƙwararru akan jiko na CAR T-Cell daga ƙwararrun ƙwararru a Singapore.
Dr. Ang Peng Tiam (MD, MRCP, FAMS, FACP)
MAGANIN LIKITA
Profile: Daraktan Likita da babban mai ba da shawara a cibiyar ciwon daji ta Parkway a sashin ilimin oncology. Dr Ang memba ne na majalisar kansilolin Singapore Cancer Society. Ya kuma kasance tsohon shugaban kungiyar Oncology ta Singapore.
Profile: Dokta Colin ya sami digirinsa na likitanci daga Jami'ar Ƙasa ta Ireland a 2002 kuma daga baya ya kammala zama na likitancin ciki da kuma horo na ƙwararru a Hematology a Babban Asibitin Singapore.
Profile: Dokta Colin ya sami digirinsa na likitanci daga Jami'ar Ƙasa ta Ireland a 2002 kuma daga baya ya kammala zama na likitancin ciki da kuma horo na ƙwararru a Hematology a Babban Asibitin Singapore.
Manyan Asibitoci Don CAR T-Cell Therapy A Singapore
Parkway Cancer Center
The sabon abu immunotherapy Hanyar da aka fi sani da CAR T-cell far ta nuna alƙawarin na musamman a cikin maganin cututtuka iri-iri. Birnin Beijing, Asibitin Ciwon daji na Jami'ar Peking na kasar Sin ya zama jagora a duniya wajen bunkasa maganin CAR T-cell. Tare da taimakon ƙungiyar su da yawa, wanda ya ƙunshi likitocin oncologists, immunologists, and geneticists, keɓaɓɓen maganin kansa ya sami ci gaba sosai. Asibitin Ciwon daji na Jami'ar Peking ya sami kyakkyawan sakamako a cikin marasa lafiya da ke da cutar hanta ta hanyar canza ƙwayoyin T na marasa lafiya don bayyana masu karɓar antigen (CARs). Wannan magani yana ba masu ciwon daji sabon bege da haɓaka ƙimar rayuwa.
Cibiyar Ciwon daji ta Jami'ar Ƙasa (NCIS) a Singapore sanannen wuri ne wanda ke aiki don kaucewa, ganowa, da kuma magance ciwon daji. A matsayin wani ɓangare na Tsarin Kiwon Lafiya na Jami'ar Ƙasa, NCIS tana ba mutanen da ke da ciwon daji cikakken kulawa da haɗin kai. Cibiyar ta haɗu da ƙwararrun asibiti, bincike mai zurfi, da ilimi don fito da tsare-tsaren jiyya na keɓaɓɓen waɗanda suka dogara akan hujjar kimiyya. NCIS tana da kayan aiki na zamani, kamar fasahar hoto na ci gaba da kayan aiki don radiation far. Suna kuma bayar da farashi mai araha proton far a Singapore.
Babban fa'idar ita ce maganin CAR T-cell yana buƙatar jiko ɗaya kawai kuma galibi yana buƙatar makonni biyu na kulawar marasa lafiya. Marasa lafiya da lymphoma ba Hodgkin da cutar sankarar yara waɗanda aka riga aka gano, a gefe guda, yawanci suna buƙata. chemotherapy akalla watanni shida ko fiye.
Amfanin CAR T-cell far, wanda shine magani mai rai, na iya dawwama shekaru da yawa. Idan kuma lokacin da sake dawowa ya faru, ƙwayoyin za su iya ganowa da kuma kai hari ga ƙwayoyin cutar kansa saboda suna iya rayuwa a cikin jiki na tsawon lokaci.
Kodayake bayanin yana ci gaba, kashi 42 cikin 19 na marasa lafiya na lymphoma manya waɗanda suka yi amfani da CD15 CAR T-cell magani har yanzu suna cikin gafara bayan watanni XNUMX. Kuma bayan watanni shida, kashi biyu bisa uku na marasa lafiya da ke fama da cutar sankarar mahaifa mai tsanani na lymphoblastic na yara har yanzu suna cikin gafara. Abin takaici, waɗannan majiyyatan suna da ciwace-ciwacen ciwace-ciwacen daji waɗanda ba a samu nasarar yi musu magani ta amfani da ƙa'idodin kulawa na gargajiya ba.
Marasa lafiya tsakanin shekaru 3 zuwa shekaru 70 sun gwada maganin CAR T-Cell don nau'ikan cututtukan daji na jini kuma yana da tasiri sosai. Cibiyoyi da yawa sun yi iƙirarin ƙimar nasara fiye da 80%. Mafi kyawun ɗan takarar don CAR T-cell far a wannan lokacin shine ƙaramin yaro tare da cutar sankarar lymphoblastic mai tsanani ko kuma balagagge tare da lymphoma mai tsanani na B-cell wanda ya riga ya sami layi biyu na rashin tasiri.
Kafin ƙarshen 2017, babu wani tsarin kulawa da aka yarda da shi ga marasa lafiya waɗanda suka riga sun shiga cikin layi biyu na jiyya ba tare da samun gafara ba. Magani kawai da FDA ta amince da shi wanda ya zuwa yanzu ya tabbatar da cewa yana da fa'ida sosai ga waɗannan marasa lafiya shine CAR T-cell far.
Yaya Tasirin CAR-T Magungunan Kwayoyin cuta?
CAR T-cell far ya kasance mai tasiri sosai wajen magance wasu nau'in ciwon daji na jini, kamar cutar sankarar bargo na lymphoblastic (ALL) da lymphoma ba Hodgkin. A cikin gwaje-gwaje na asibiti, ƙimar amsawar sun kasance da kyau sosai, kuma yawancin marasa lafiya sun shiga cikin cikakkiyar gafara. A wasu lokuta, mutanen da suka gwada kowane magani sun sami gafara na dindindin ko ma yiwuwar warkewa.
Ɗaya daga cikin mafi kyawun abubuwa game da maganin CAR T-cell shine cewa yana kai hari ga ƙwayoyin da suka dace. Masu karɓar CAR waɗanda aka ƙara zuwa ƙwayoyin T suna iya samun takamaiman alamomi akan ƙwayoyin cutar kansa. Wannan yana ba da damar ba da magani da aka yi niyya. Wannan hanyar da aka yi niyya tana cutar da ƙwayoyin lafiya kaɗan gwargwadon yuwuwa kuma tana rage haɗarin illolin da ke zuwa tare da jiyya na gargajiya kamar chemotherapy.
Amma yana da mahimmanci a tuna cewa CAR T-cell far har yanzu wani sabon yanki ne wanda har yanzu yana canzawa. Masu bincike da likitoci suna aiki tuƙuru don magance matsaloli kamar tsadar tsada, yuwuwar sakamako mai tsanani, da gaskiyar cewa yana aiki ne kawai ga wasu nau'ikan cutar kansa.
A ƙarshe, maganin CAR T-cell ya nuna hanya ce mai nasara sosai don magance wasu nau'in ciwon daji na jini. Ko da yake hanya ce mai ban sha'awa da ƙarfi, ana buƙatar ƙarin nazari da gwaje-gwaje na asibiti don inganta shi da kuma nemo sababbin hanyoyin amfani da shi. CAR T-cell far na iya canza yadda ake bi da kansa kuma ya sa abubuwa su zama mafi kyau ga mutane a duk faɗin duniya idan ta ci gaba da samun gyaruwa.
Wanene Ya Cancanci Gasar CAR T Cell A Singapore?
A cikin Singapore, cancanta don CAR T Cell Therapy zaɓi ne kuma an keɓance shi don iyakar tasiri.
Marasa lafiyan da suka cancanta su ne yara da matasa (shekaru 3-25) waɗanda ke da cutar sankarar barna ta B-cell M Cute Lymphoblastic Leukemia (ALL) waɗanda suka sake dawowa bayan dasawa.
CAR T Cell Therapy kuma yana samuwa ga manya masu Diffus Large B-cell Lymphoma (DLBCL) waɗanda ba su amsa aƙalla daidaitattun jiyya guda biyu ba.
Koyaya, wasu ƙungiyoyin majiyyata bazai cika ka'idodin cancanta ba, gami da waɗanda ke da hauhawar jini na ciki ko rashin sani, gazawar numfashi, yaɗawar coagulation na intravascular, hematosepsis, ko kamuwa da cuta mai aiki mara ƙarfi da ciwon sukari. Zaɓin zaɓin da ya dace na marasa lafiya yana tabbatar da cewa CAR T Cell Therapy an ba da ita ga mutanen da za su amfana da mafi yawan, ƙara yiwuwar samun kyakkyawan sakamako na jiyya.
CAR T-Cell Magungunan da USFDA Ta Amince
KYMRIAH
B-cell precursor m lymphoblastic cutar sankarar bargo, koma baya ko refractory yaduwa babban B-cell lymphoma
Cikakken ƙimar amsawa (CR):> 90%
Saukewa: CD19
Farashin: $ 475,000
Lokacin amincewa: Agusta 30, 2017
YASCARTA
Mai sake dawowa ko refractory yana yaduwa babban lymphoma na B-cell, relapsed ko refractory follicular cell lymphoma
Cikakkun martanin Cikakkun Amsa na Ciwon lymphoma ba Hodgkin (CR): 51%
Saukewa: CD19
Farashin: $ 373,000
Lokacin amincewa: Oktoba 2017, 18
TECARTUS
Maimaitawa ko mai jujjuyawa yana yaduwa babban lymphoma na B-cell
Cikakkar amsa ƙimar lymphoma na Mantle cell (CR): 67%
Saukewa: CD19
Farashin: $ 373,000
Lokacin da aka amince: Oktoba 18, 2017
BREYANZI
Maimaitawa ko mai jujjuyawa yana yaduwa babban lymphoma na B-cell
Cikakken ƙimar amsawa (CR): 54%
Saukewa: CD19
Farashin: $ 410,300
Lokacin da aka amince: Oktoba 18, 2017
ABECMA
Maimaitawa ko Mai Rarraba Multiple Myeloma
Cikakken ƙimar amsawa: 28%
Saukewa: CD19
Farashin: $ 419,500
An amince da shi: Oktoba 18, 2017
Menene Illolin Kwayoyin CAR-T?
A ƙasa akwai wasu illolin maganin CAR T-Cell.
Ciwon saki na cytokine (CRS): Mafi rinjaye kuma mai yuwuwa gagarumin tasirin maganin CAR T-cell shine ciwon saki na cytokine (CRS). Alamu masu kama da mura, gami da zazzabi, gajiya, ciwon kai, da ciwon tsoka, ana kawo su ta hanyar gyare-gyaren ƙwayoyin T na cytokines. A cikin matsanancin yanayi, CRS na iya haifar da matsanancin zafin jiki, hauhawar jini, gazawar gabobin jiki, har ma da sakamako mai illa.
Gubar Neurological: Wasu marasa lafiya na iya haifar da sakamako masu illa na jijiyoyi, wanda zai iya bambanta da tsanani daga ƙananan alamu kamar ruɗani mai sauƙi da rashin fahimta zuwa mafi tsanani kamar seizures, delirium, da encephalopathy. Bayan jiko na T-cell na CAR, yawan guba na jijiyoyin jiki yana faruwa akai-akai a cikin makon farko.
Cytopenia: Maganin CAR T-cell zai iya haifar da ƙananan ƙwayoyin jini, irin su anemia (ƙananan ƙwayar jinin jini), neutropenia (ƙananan ƙwayar jinin jini), da kuma maganin ƙwaƙwalwar ƙwaƙwalwa (ƙananan adadin platelet). Cututtuka, zub da jini, da gajiyawa suna cikin haɗarin da waɗannan cytopenia za su iya tsananta.
Cututtuka: CAR T-cell therapy's ƙwanƙwasa ƙwayoyin rigakafi masu lafiya yana ƙara haɗarin ƙwayoyin cuta, ƙwayoyin cuta, da fungal. Domin hana kamuwa da cututtuka, ana iya buƙatar majiyyata a sa ido sosai kuma a ba su magunguna na rigakafi.
Tumor Lysis Syndrome (TLS): After CAR T-cell therapy, it’s possible in some circumstances for substantial amounts of cell contents to be released into the bloodstream due to the rapid killing of tumo cells. This may result in metabolic abnormalities, such as excessive potassium, uric acid, and phosphate levels, which may damage the kidneys and cause other problems.
Hypogammaglobulinemia: Maganin CAR T-cell yana da yuwuwar rage ƙwayar ƙwayar cuta, wanda zai iya haifar da hypogammaglobulinemia. Wannan na iya sa kamuwa da cuta mai maimaitawa ya fi yuwuwa kuma yana kira don ci gaba da maye gurbin maganin rigakafi.
Yawan Guba: CAR T-cell far yana da yuwuwar cutar da gabobin da dama, gami da zuciya, huhu, hanta, da koda. Wannan na iya haifar da gwaje-gwajen aikin koda mara kyau, al'amuran numfashi, matsalolin zuciya, da gwajin aikin hanta mara kyau.
Hemophagocytic lymphohistiocytosis (HLH): Cutar da ba kasafai ba amma mai yiwuwa mai saurin kisa da ake kira hemophagocytic lymphohistiocytosis (HLH) na iya tasowa a sakamakon maganin CAR T-cell. Ya haɗa da wuce gona da iri na ƙwayoyin rigakafi, wanda ke haifar da mummunar lalacewar gabobin da kumburi.
Hypotension da Riƙewar Ruwa: Sakamakon cytokines da ƙwayoyin CAR T suka saki, wasu marasa lafiya na iya haifar da ƙananan hawan jini (hypotension) da riƙewar ruwa. Don magance waɗannan alamomin, ana iya buƙatar matakan tallafi gami da ruwan jijiya da magunguna.
Malignancin Sakandare: Rahotanni na malignancies na biyu da ke fitowa bayan maganin CAR T-cell sun wanzu, duk da ƙarancinsu. A halin yanzu ana gudanar da bincike kan yuwuwar kamuwa da cutar ta biyu da kuma haɗari na dogon lokaci.
Yana da mahimmanci a tuna cewa ba kowane majiyyaci ne zai sami waɗannan illolin ba kuma matakin hankalin kowane mutum zai bambanta. Don ragewa da rage girman waɗannan abubuwan da zasu iya haifar da illa, ƙungiyar likitocin suna bincikar marasa lafiya sosai kafin, lokacin, da kuma bayan maganin CAR T-cell.
Lokaci
Bincika ƙasa jimlar firam ɗin lokacin da ake buƙata don kammala tsarin jiyya na CAR T-Cell. Koyaya, tsarin lokaci ya dogara da yawa akan nisan dakin gwaje-gwaje daga asibitin da ya shirya CARs.
Ta Yaya Zamu Iya Taimaka muku Samun Mafi kyawun CAR T Cell Therapy A Singapore?
Nemo madaidaicin CAR-T Therapy a Singapore na iya zama da wahala, amma mu a Fax Cancer muna nan don taimaka muku kowane mataki na hanya. Mun fahimci mahimmancin lafiyar ku, kuma sadaukar da ingancin kulawa ba zaɓi bane. Mun gina haɗin gwiwa tare da ƙwararrun likitoci kuma mun haɗu tare da sanannun asibitoci da yawa don ba ku zaɓi na wuraren farashi waɗanda suka dace da bukatunku, kamar amintaccen aboki. Burin mu shine mu taimaka muku samun mafi kyawun CAR T Cell Therapy ba tare da sanya damuwa akan kuɗin ku ba. Hanyarmu ta gaba ɗaya game da kula da ciwon daji ta riga ta tallafa wa marasa lafiya daga ƙasashe daban-daban. Amince da mu don jagorance ku da kuma tabbatar da cewa kun sami mafi kyawun magani don yaƙar cutar kansa kuma ku sami lafiya nan ba da jimawa ba.
Fara hira
Muna Kan layi! Yi Taɗi da Mu!
Duba lambar
Hello,
Barka da zuwa CancerFax!
CAR T Cell therapy a Singapore farashin tsakanin 450,000 zuwa 500,000 USD, ya danganta da nau'i da matakin cutar da kuma asibitin da aka zaɓa.
Da fatan za a aiko mana da rahoton ku na likitanci, kuma za mu dawo muku da cikakkun bayanai na jiyya, asibiti, da kiyasin farashi.
